- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03564899
The Breast Cancer & Physical Activity Level (BC-PAL) Pilot Study (BC-PAL)
Study Overview
Status
Conditions
Detailed Description
Detailed Description
Rationale and Significance:
Breast cancer is the most common cancer among Canadian women. Physical activity has emerged as a potential lifestyle factor for improving rehabilitation and survival after breast cancer. The American Cancer Society recommends that cancer survivors engage in at least 150 minutes of moderate-vigorous intensity physical activity per week. However, only ≈ 15% of breast cancer survivors reported meeting these physical activity guidelines. Therefore, interventions that promote physical activity behavior change in an unsupervised/home-based setting are needed to provide the necessary tools and support for breast cancer survivors. No study to date has assessed the effects of a lighter intensity physical activity intervention, compared to no additional physical activity prescription (control) or a higher intensity physical activity intervention (comparable to current exercise guidelines), in inactive breast cancer survivors, in addition to the longer-term maintenance effects of these interventions.
Study Aims:
Aim 1: To evaluate the effects of prescribing an additional 300 minutes/week of lighter intensity physical activity (LIPA) or 150 minutes/week of higher intensity physical activity (HIPA) versus no physical activity intervention (control) on total physical activity and sedentary time in inactive breast cancer survivors.
Aim 2: To evaluate the effects of prescribing an additional 300 minutes/week of LIPA or 150 minutes/week of HIPA versus control on markers of health-related fitness (anthropometric measures, body composition, cardio-respiratory fitness) and patient reported outcomes (quality of life, sleep quality, feelings of happiness, perceived feelings of depression) in inactive breast cancer survivors.
Aim 3: To evaluate the longer-term (24-week) maintenance effect of prescribing an additional 300 minutes/week of LIPA or 150 minutes/week of HIPA versus control on our primary and secondary outcomes.
Research Plan:
A three-armed, 12-week pilot randomized controlled trial followed by a 12-week follow-up measurement is proposed. All eligible and interested women are invited to contact and meet with study staff at the Holy Cross Center in Calgary, at which time the study protocol is explained, informed consent obtained and baseline questionnaires distributed. These questionnaires assess: demographic characteristics, sleep quality, perceived health-related quality of life, feelings of happiness and perceived feelings of depression. At the end of this first meeting, participants are asked to wear an Actigraph GTX3® accelerometer for seven days to assess baseline physical activity levels. During a second meeting at the Holy Cross Center, accelerometers are returned to study staff, anthropometric data (height, weight, waist and hip circumferences and body composition) are collected and a maximal treadmill test (modified Balke protocol) is conducted. Participants are then randomized, using a 1:1:1 allocation, into either the control (no intervention), lighter intensity or the higher intensity physical activity interventions. The control group is instructed to maintain baseline physical activity participation. The lighter intensity physical activity (LIPA) group is instructed to accumulate 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve. The higher intensity physical activity (HIPA) group is instructed to accumulate 150 minutes of physical activity at an intensity of 60-80% of heart rate reserve. Participants randomized to the LIPA and HIPA groups are given: 1) instructions on physical activity safety and goal setting, proper heart rate monitoring and stretching techniques that should be completed before and after physical activity participation; 2) a publicly-available physical activity guidebook for breast cancer survivors; 3) a Polar A360® device to track heart rate and physical activity time throughout the intervention. Data collected by this device are uploaded to the Polar Flow® application by syncing with a smart phone or a computer with a provided USB cord. Participants are asked to upload their data at least once per week. If a participant does not own a computer or a smart phone, or prefers that the study staff upload these data for them, in-person meetings are arranged to do so. Participants in the LIPA and HIPA groups are also asked to rate the feasibility of achieving the prescribed physical activity targets and record strategies used and barriers encountered during the intervention in a diary. In-person/telephone meetings with these participants occur every three weeks to review data from the Polar A360® device and diary, to reinforce progress/good adherence and discuss/solve any problems or barriers to achieving the prescribed physical activity goals. During weeks 12 (final intervention week) and 24 (final week of the follow-up period), all participants wear an Actigraph GTX3® accelerometer to assess physical activity volume. At the end of weeks 12 (end of the intervention) and 24 (end of the follow-up period), all participants repeat baseline measurements and questionnaires, except for items on demographic characteristics.
The investigators will use intention-to-treat statistical analysis on all participants with follow-up data regardless of adherence to the interventions. An analysis of covariance (ANCOVA) will be used to compare between-group differences in study outcomes at 12- and 24-weeks, compared to baseline, after adjusting for baseline outcomes values.
This pilot randomized controlled trial will provide data on the feasibility of prescribing different physical activity intensities within a home-based setting to increase total physical activity time, reduce sedentary time and improve health outcomes in breast cancer survivors. The investigators will use these data to help design and conceptualize a larger-scale randomized controlled trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2S 3C3
- The Rehabilitation, Exercise and Complementary (REACH) center within the Holy Cross Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically-confirmed Stage I-III breast cancer diagnosis
- Completion of adjuvant treatment (chemotherapy, radiation therapy and surgery) except for hormone therapy
- Females ≥18 years of age
- Currently living in the Calgary area and able to meet with study staff at the Holy Cross Center on at least six occasions (twice as baseline, 12- and 24-weeks)
- Currently inactive (accumulating ≤ 60 minutes of moderate-vigorous intensity physical activity/week and ≤ 10,000 steps/day)
- Ability to undertake a physical activity program [assessed by an Exercise Physiologist with the Physical Activity Readiness Questionnaire (PAR-Q+)].
Exclusion Criteria:
- Deemed too active (accumulating on average ≥ 60 minutes of moderate-vigorous intensity physical activity/week and ≥ 10,000 steps/day)
- Being away from Calgary or not able to attend testing sessions/be contacted by study staff for > 4 consecutive weeks during the intervention period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control
Receive no physical activity intervention (maintain baseline physical activity participation)
|
|
Experimental: Lighter intensity physical activity
Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
|
Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
|
Active Comparator: Higher intensity physical activity
Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
|
Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sedentary time, light intensity physical activity time and moderate-vigorous intensity physical activity time (hours/day)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Measured with accelerometry over seven days
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body weight (kg)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Measured with a standard beam scale
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Change in height (cm)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Measured with a stadiometer
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Change in waist and hip circumference (cm)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Measured with an anthropometric measuring tape
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Change in body composition (fat and lean mass in kg)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Measured by Dual X-ray Absorptiometry (DXA)
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Change in cardiorespiratory fitness (VO2max)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Measured by maximal cardiorespiratory fitness test using the multistage, modified Balke treadmill protocol
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Change in body mass index (BMI in kg/m2)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Weight and height will be combined to report BMI
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sleep quality (scale of 0 to 21)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Pittsburgh Sleep Quality Index will be used to measure the total aggregate score from the questionnaire on a scale of 0-21, with 21 indicating worst sleep quality
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Change in health-related quality of life (scale of 0 to 100)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
The Medical Outcomes Study Short Form-12 Survey will be used to measure mental component aggregate score and physical component aggregate score, each on a scale of 0-100, with a higher score indicating higher function, well-being or quality of life.
The questions on physical functioning, role-physical limitations and bodily pain are summed to provide the physical aggregate score.
The questions on social functioning, vitality, role-emotional limitations and mental health are summed to provide the mental aggregate score.
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Change in breast cancer-specific quality of life (scale of 0 to 28)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
The Functional Assessment of Cancer Therapy-Breast Questionnaire will be used to measure total score ranges from 0 to 28, with a higher score indicating higher function, well-being or quality of life.
The results from each question are summed to provide the total score.
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Changes in feelings of happiness (scale of 1 to 11 and value in % over past 7 days)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
The Happiness Scale will be used to assess happiness with one question asking participants what is the average level of happiness over the past 7 days on a scale of 1 (extremely happy) to 11 (extremely unhappy).
A second question asks participants what is the percentage of time spent happy (value in % over the last 7 days), neutral (value in % over the last 7 days) and unhappy (value in % over the last 7 days).
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Changes in perceived feelings of depression (scale from 0 to 27)
Time Frame: Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
The Patient Health Questionnaire provides a score of 0 to 27, with a higher score indicating higher feelings of depression.
The results from each question are summed to provide the total score.
|
Baseline, 12 weeks (end of intervention) and 24 weeks (end of follow-up period)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christine Friedenreich, PhD, CancerControl Alberta
- Study Director: Jessica McNeil, PhD, CancerControl Alberta
Publications and helpful links
General Publications
- McNeil J, Fahim M, Stone CR, O'Reilly R, Courneya KS, Friedenreich CM. Adherence to a lower versus higher intensity physical activity intervention in the Breast Cancer & Physical Activity Level (BC-PAL) Trial. J Cancer Surviv. 2022 Apr;16(2):353-365. doi: 10.1007/s11764-021-01030-w. Epub 2021 Mar 22.
- McNeil J, Brenner DR, Stone CR, O'Reilly R, Ruan Y, Vallance JK, Courneya KS, Thorpe KE, Klein DJ, Friedenreich CM. Activity Tracker to Prescribe Various Exercise Intensities in Breast Cancer Survivors. Med Sci Sports Exerc. 2019 May;51(5):930-940. doi: 10.1249/MSS.0000000000001890.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BC-PAL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Survivorship
-
National University, SingaporeNational Cancer Centre, SingaporeUnknownBreast Cancer | Gynecologic Cancer | SurvivorshipSingapore
-
Mount Mary UniversityCompletedBreast Cancer Female | SurvivorshipUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)CompletedBreast Cancer Female | Survivorship | Early-stage Breast Cancer | Cancer Survivors | Transitional CareUnited States
-
National Cancer Centre, SingaporeSingHealth Polyclinics; National University of SingaporeCompletedBreast Cancer | SurvivorshipSingapore
-
Manuela EicherSwiss Cancer League; Lindenhofgruppe AGCompletedBreast Neoplasm | Self-Management | Intervention | Cancer Survivorship | Early-Stage Breast CancerSwitzerland
-
Massachusetts General HospitalKully Family FoundationCompletedBreast Cancer | Breast Cancer Recurrent | Fasting | SurvivorshipUnited States
-
Comprehensive Cancer Centre The NetherlandsBorstkanker Onderzoek Groep; University of Twente; Dutch Breast Cancer Association and other collaboratorsEnrolling by invitationBreast Cancer | Breast Cancer Female | SurvivorshipNetherlands
-
Istanbul Medipol University HospitalThe Scientific and Technological Research Council of TurkeyEnrolling by invitationHealth Behavior | Breast Cancer Female | SurvivorshipTurkey
-
Istanbul Breast SocietyCompletedBreast Cancer | Breast Neoplasms | Survivorship | Radiotherapy; ComplicationsTurkey
-
Cedars-Sinai Medical CenterRecruitingCancer | SurvivorshipUnited States
Clinical Trials on Lighter intensity physical activity intervention
-
Brown UniversityNational Institute on Aging (NIA)RecruitingPhysical InactivityUnited States
-
Anne Birgitte RabenUniversity of Nottingham; University of Helsinki; Wageningen University; University... and other collaboratorsCompletedObesity | Pre-diabetesSpain, Denmark, Australia, Bulgaria, Finland, Netherlands, New Zealand, United Kingdom
-
University of Vic - Central University of CataloniaIRIS-CC; AGAUREnrolling by invitation
-
Brown UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
University of ConnecticutNational Institutes of Health (NIH); National Center for Complementary and...RecruitingChronic Low Back PainUnited States
-
University of Missouri-ColumbiaCompletedObesity | Metabolic SyndromeUnited States
-
Gunma PAZ CollegeKanazawa UniversityCompletedPhysical Activity | Hemiplegia | Motor ActivityJapan
-
Western University, CanadaEast Elgin Family Health TeamRecruiting
-
Institut Català d'OncologiaUnknownRecurrence | Breast NeoplasmsSpain
-
Centre Leon BerardNational Cancer Institute, FranceNot yet recruitingMetastatic Testicular CancerFrance